Eli Lilly's Combination Therapy Shows Promising Results in Psoriatic Arthritis
Eli Lilly has reported promising results from a late-stage trial combining Zepbound with Taltz, showing significant improvements in psoriatic arthritis symptoms and weight loss. The trial demonstrated a 31.7% response rate for the combination compared to 0.8% for Taltz alone, highlighting a potential new dual-indication strategy.
Insights:
Eli Lilly and Company announced on January 8, 2026, that its late-stage clinical trial results reveal promising outcomes for patients with psoriatic arthritis when treated with a combination of Zepbound and Taltz. The study demonstrated that 31.7% of patients receiving the combination therapy achieved a significant reduction in disease activity and weight loss, compared to only 0.8% of those treated with Taltz alone.
